LYEL Stock Price History and Quote Analysis Insights for Investors
Lyell Immunopharma, Inc.
Stock Price Today
Lyell Immunopharma, Inc. (LYEL) stock declined over -2.35%, trading at $0.92 on NASDAQ, down from the previous close of $0.94. The stock opened at $0.95, fluctuating between $0.91 and $0.97 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Company Information
| Employees | 224 |
| Beta | -0.48 |
| Sales or Revenue | $130.00K |
| 5Y Sales Change% | -0.806% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Lyell Immunopharma, Inc. (NASDAQ: LYEL) stock price is $0.92 in the last trading session. During the trading session, LYEL stock reached the peak price of $0.97 while $0.91 was the lowest point it dropped to. The percentage change in LYEL stock occurred in the recent session was -2.35% while the dollar amount for the price change in LYEL stock was -$0.02.
The NASDAQ listed LYEL is part of Biotechnology industry that operates in the broader Healthcare sector. Lyell Immunopharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Nellie Dillery
Director of Accounting
Dr. Richard D. Klausner M.D.
Founder & Executive Chairman
Dr. Crystal L. Mackall M.D.
Founder & Scientific Advisor
Dr. Lynn Seely M.D.
Pres, Chief Executive Officer & Director
Ms. Elizabeth Homans
Consultant
Dr. Gary Lee Ph.D.
Chief Scientific Officer
Prof. Stanley R. Riddell M.D.
Founder & Scientific Advisor
Mr. Stephen J. Hill
Chief Operating Officer
Mr. Charles W. Newton
Chief Financial Officer
Mr. Richard Goold Ph.D.
Chief Information Officer
Ellen Rose
Vice President of Communications & Investor Relations
Dr. Lynn Seely M.D., Ph.D.
Pres, Chief Executive Officer & Director
Ms. Ellen Rose
Senior Vice President of Communications & Investor Relations
Mr. Rahsaan W. Thompson J.D.
Chief Legal Officer & Corporation Sec.
LYEL's closing price is 8.23% higher than its 52-week low of $0.85 where as its distance from 52-week high of $3.26 is -71.74%.
Number of LYEL employees currently stands at 224.
Official Website of LYEL is: https://www.lyell.com
LYEL could be contacted at phone 650 695 0677 and can also be accessed through its website. LYEL operates from 201 Haskins Way, South San Francisco, CA 94080, United States.
LYEL stock volume for the day was 1.18M shares. The average number of LYEL shares traded daily for last 3 months was 1.29M.
The market value of LYEL currently stands at $268.79M with its latest stock price at $0.92 and 292.16M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com